Potential survival benefit of polymyxin B hemoperfusion in patients with septic shock: a propensity-matched cohort study

Table 3 Mortality and number of IUCFDs in the propensity-matched groups analyses

Variables	Unmatched group						Matched group
Variables	non-PMX-HP (n = 1201)	PMX-HP (n = 522)	OR	Difference	95% CI	P value	non-PMX-HP (n = 262)	PMX-HP (n = 262)	OR	Difference	95% CI	P value
All-cause hospital mortality, n (%)	439 (36.6)	198 (37.9)	1.061		(0.858–1.312)	0.585	108 (41.2)	86 (32.8)	0.681		(0.470–0.987)	0.042
ICU mortality, n (%)	268 (22.3)	128 (24.5)	1.131		(0.889–1.440)	0.317	64 (24.4)	57 (21.8)	0.844		(0.548–1.300)	0.443
28 ICUFDs (days)	16 (0–23)	15 (0–21)		0.0	(0.0–0.0)	0.255	14 (0–22)	18 (0–22)		1.5	(0.0–3.5)	0.045

Data are presented as median (first quartile to third quartile) or number (percentage)
In the unmatched group, categorical variables were compared by logistic regressions, and continuous variables were compared by Wilcoxon tests and Hodges-Lehmann estimates were presented for difference and 95% CI. In the matched group, all-cause hospital mortality and ICU mortality were analyzed by conditional logistic regression including PMX-DHP as a covariate and matched-set as a stratum, and ICUFDs were analyzed by signed rank test and Hodges-Lehmann estimate was presented for difference and 95% CI
CI confidence interval, ICU intensive care unit, ICUFDs ICU-free days, OR odds ratio, PMX-HP polymyxin B hemoperfusion

ISSN: 1364-8535